Self-Host
Tools / Inside Trading Tracker
Inside Trading Tracker
Track insider trading activity at publicly traded companies to understand how executives are trading their shares.
Ani Pharmaceuticals Inc. (ANIP) Insider Trading Activity
Healthcare • Drug Manufacturers - Specialty & Generic • 642 employees
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.
Total Value
-$4,301,127.71
Total Shares
312,728
Average Trade Value
-$93,502.78
Most Active Insider
Lalwani Nikhil
Total Activity: $4,037,008
Largest Single Transaction
$1,738,500
by Lalwani Nikhil on Nov 26, 2024
30-Day Activity
0 Transactions
Volume: 0 shares
Value: $0
|
Name
|
Position
|
Date
|
Shares
|
Value
|
Holdings
|
Type
|
|---|---|---|---|---|---|---|
|
Sr. Vp, General Counsel Sec.
Officer
|
Feb 28, 2025 | 1,099 | $68,017 | 80,945 (-1.4%) | Payment of Exercise Price | |
|
President CEO
Director, Officer
|
Feb 28, 2025 | 12,216 | $756,048 | 502,694 (-2.4%) | Payment of Exercise Price | |
|
Svp, Head - Established Brands
Officer
|
Feb 28, 2025 | 627 | $38,805 | 45,465 (-1.4%) | Payment of Exercise Price | |
|
Head of Rare Disease
Officer
|
Feb 28, 2025 | 1,275 | $78,910 | 114,191 (-1.1%) | Payment of Exercise Price | |
|
SVP CFO
Officer
|
Feb 28, 2025 | 1,861 | $115,177 | 192,223 (-1.0%) | Payment of Exercise Price | |
|
Svp, Chief Hr Officer
Officer
|
Feb 28, 2025 | 1,099 | $68,017 | 67,525 (-1.6%) | Payment of Exercise Price | |
|
Svp, Generics
Officer
|
Feb 28, 2025 | 1,570 | $97,167 | 99,176 (-1.6%) | Payment of Exercise Price | |
|
Svp, Chief Hr Officer
Officer
|
Feb 21, 2025 | 1,000 | $60,200 | 68,624 (-1.5%) | Sale | |
|
Head of Rare Disease
Officer
|
Feb 15, 2025 | 1,184 | $69,761 | 115,466 (-1.0%) | Payment of Exercise Price | |
|
Svp, Generics
Officer
|
Feb 15, 2025 | 1,167 | $68,760 | 100,746 (-1.2%) | Payment of Exercise Price | |
|
SVP CFO
Officer
|
Feb 14, 2025 | 1,730 | $101,932 | 194,084 (-0.9%) | Payment of Exercise Price | |
|
Svp, Generics
Officer
|
Feb 14, 2025 | 1,426 | $84,020 | 101,913 (-1.4%) | Payment of Exercise Price | |
|
Head of Rare Disease
Officer
|
Feb 14, 2025 | 1,473 | $86,789 | 116,650 (-1.3%) | Payment of Exercise Price | |
|
Sr. Vp, General Counsel Sec.
Officer
|
Feb 14, 2025 | 1,434 | $84,491 | 82,044 (-1.7%) | Payment of Exercise Price | |
|
President CEO
Director, Officer
|
Feb 14, 2025 | 7,799 | $459,517 | 514,910 (-1.5%) | Payment of Exercise Price | |
|
Svp, Chief Hr Officer
Officer
|
Feb 14, 2025 | 1,196 | $70,468 | 69,624 (-1.7%) | Payment of Exercise Price | |
|
Svp, Head - Established Brands
Officer
|
Feb 14, 2025 | 582 | $34,291 | 46,092 (-1.3%) | Payment of Exercise Price | |
|
Sr. Vp, General Counsel Sec.
Officer
|
Feb 13, 2025 | 400 | $23,816 | 83,478 (-0.5%) | Sale | |
|
Svp, Generics
Officer
|
Feb 12, 2025 | 10,444 | $10,000 | 103,339 (+10.1%) | Grant | |
|
SVP CFO
Officer
|
Feb 12, 2025 | 16,538 | $10,000 | 195,814 (+8.4%) | Grant | |
|
Head of Rd, Coo-novitium Ops
Director, Officer
|
Feb 12, 2025 | 9,574 | $10,000 | 92,588 (+10.3%) | Grant | |
|
Head of Rare Disease
Officer
|
Feb 12, 2025 | 24,808 | $0 | 101,585 (+24.4%) | Grant | |
|
Svp, Generics
Officer
|
Feb 12, 2025 | 15,668 | $0 | 92,895 (+16.9%) | Grant | |
|
Head of Rare Disease
Officer
|
Feb 12, 2025 | 16,538 | $10,000 | 118,123 (+14.0%) | Grant | |
|
Svp, Head - Established Brands
Officer
|
Feb 12, 2025 | 5,222 | $10,000 | 46,674 (+11.2%) | Grant | |
|
President CEO
Director, Officer
|
Feb 12, 2025 | 91,399 | $0 | 461,777 (+19.8%) | Grant | |
|
Svp, Chief Hr Officer
Officer
|
Feb 12, 2025 | 8,704 | $10,000 | 70,820 (+12.3%) | Grant | |
|
Sr. Vp, General Counsel Sec.
Officer
|
Feb 12, 2025 | 11,316 | $10,000 | 83,878 (+13.5%) | Grant | |
|
Svp, Head - Established Brands
Officer
|
Feb 12, 2025 | 7,834 | $0 | 41,452 (+18.9%) | Grant | |
|
President CEO
Director, Officer
|
Feb 12, 2025 | 60,932 | $10,000 | 522,709 (+11.7%) | Grant | |
|
SVP - Corp. Dev. Strategy
Officer
|
Feb 12, 2025 | 9,574 | $10,000 | 73,615 (+13.0%) | Grant | |
|
SVP - Corp. Dev. Strategy
Officer
|
Feb 12, 2025 | 14,362 | $0 | 64,041 (+22.4%) | Grant | |
|
Sr. Vp, General Counsel Sec.
Officer
|
Feb 12, 2025 | 16,974 | $0 | 72,562 (+23.4%) | Grant | |
|
Svp, Chief Hr Officer
Officer
|
Feb 12, 2025 | 13,057 | $0 | 62,116 (+21.0%) | Grant | |
|
SVP CFO
Officer
|
Feb 12, 2025 | 24,808 | $0 | 179,276 (+13.8%) | Grant | |
|
Head of Rd, Coo-novitium Ops
Director, Officer
|
Feb 12, 2025 | 14,362 | $0 | 83,014 (+17.3%) | Grant | |
|
Sr. Vp, General Counsel Sec.
Officer
|
Jan 13, 2025 | 400 | $21,568 | 55,588 (-0.7%) | Sale | |
|
SVP CFO
Officer
|
Dec 17, 2024 | 7,500 | $418,425 | 154,468 (-4.9%) | Sale | |
|
Sr. Vp, General Counsel Sec.
Officer
|
Dec 13, 2024 | 250 | $14,060 | 55,988 (-0.4%) | Sale | |
|
Svp, Chief Hr Officer
Officer
|
Dec 11, 2024 | 1,000 | $60,000 | 49,059 (-2.0%) | Sale | |
|
President CEO
Director, Officer
|
Nov 26, 2024 | 3,481 | $202,942 | 370,378 (-0.9%) | Sale | |
|
President CEO
Director, Officer
|
Nov 26, 2024 | 30,000 | $870,000 | 403,859 (+7.4%) | Exercise/Conversion | |
|
President CEO
Director, Officer
|
Nov 26, 2024 | 30,000 | $1,738,500 | 373,859 (-8.0%) | Sale | |
|
Svp, Head - Established Brands
Officer
|
Nov 15, 2024 | 867 | $49,055 | 33,169 (-2.6%) | Payment of Exercise Price | |
|
Head of Rare Disease
Officer
|
Nov 15, 2024 | 6,500 | $375,050 | 76,777 (-8.5%) | Sale | |
|
Sr. Vp, General Counsel Sec.
Officer
|
Nov 13, 2024 | 250 | $15,340 | 56,238 (-0.4%) | Sale |